Tamara Rordorf
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Doughnut-shaped bone lesions on 18F-FDG-PET/CT may indicate pseudoprogression under immuno(radio)therapy.
Journal: Annals of nuclear medicine
Published: December 10, 2025
Distant Pulmonary Metastasis in Microsecretory Adenocarcinoma of the Salivary Gland: A Case Report Highlighting Histological Variation and Aggressive Potential.
Journal: International journal of surgical pathology
Published: November 03, 2025
Metastatic and recurrent salivary gland carcinoma: clinical characteristics and comprehensive molecular profiling at a tertiary care center.
Journal: Journal of cancer research and clinical oncology
Published: September 01, 2025
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.
Journal: Experimental hematology & oncology
Published: June 10, 2025
Biological behavior of DCIS with or without microinvasion. Same and different.
Journal: Human pathology
Published: June 02, 2025
Survival outcomes after systemic treatment of high-grade triple-negative metaplastic breast cancer versus triple-negative breast cancer of no special type.
Journal: Virchows Archiv : an international journal of pathology
Published: May 26, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 16, 2024
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 04, 2023
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 11, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 25, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Journal: Oral oncology
Published: November 10, 2021
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Journal: The oncologist
Published: June 26, 2021
Last Updated: 09/26/2026